A similar double-blind, controlled, randomized clinical trial conducted later by LeWitt et al., investigated the same AAV2-GAD vector for bilateral subthalamic delivery in advanced PD patients, and showed similar results of safety and improvement of motor function [230]. This evidence concerns the gene GAD1 and Parkinson disease.